Prospective Evaluation of the Strategy of Functionally Optimized Coronary Intervention

J Am Heart Assoc. 2020 Feb 4;9(3):e015073. doi: 10.1161/JAHA.119.015073. Epub 2020 Jan 30.

Abstract

Background Long-term outcomes after percutaneous coronary intervention (PCI) relate in part to residual ischemia in the treated vessel, as reflected by post-PCI fractional flow reserve (FFR). The strategy of FFR after PCI and treatment of residual ischemia-known as functionally optimized coronary intervention (FCI)-may be feasible and capable of improving outcomes. Methods and Results Feasibility and results of FCI using an optical-sensor pressure wire were prospectively evaluated in an all-comer population with 50% to 99% lesions and ischemic FFR (≤0.80; ClinicalTrials.gov identifier NCT03227588). FCI was attempted in 250 vessels in 226 consecutive patients. The PCI success rate was 99.6% (249/250 vessels). FCI technical success-that is, FFR before and after PCI and PCI itself using the FFR wire-was 92% (230/250 vessels). Incidence of residual ischemia in the treated vessel was 36.5%. Approximately a third of these vessels (34.5%, n=29) were considered appropriate for further intervention, with FFR increasing from 0.71±0.07 to 0.81±0.06 (P<0.001). Pressure wire pullback showed FFR ≤0.8 at distal stent edge was 7.9% and 0.7% proximal to the stent. FFR increase across the stent was larger in the ischemic than in the nonischemic group (0.06 [interquartile range: 0.04-0.08] versus 0.03 [interquartile range: 0.01-0.05]; P<0.0001) compatible with stent underexpansion as a contributor to residual ischemia. Conclusions FCI is a feasible and safe clinical strategy that identifies residual ischemia in a large proportion of patients undergoing angiographically successful PCI. Further intervention can improve ischemia. The impact of this strategy on long-term outcomes needs further study.

Keywords: coronary revascularization; coronary stenting; fractional flow reserve; functional coronary intervention; ischemia; percutaneous coronary intervention.

MeSH terms

  • Aged
  • Cardiac Catheterization*
  • Coronary Angiography
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / physiopathology
  • Coronary Artery Disease / therapy*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / physiopathology*
  • Feasibility Studies
  • Fractional Flow Reserve, Myocardial*
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / instrumentation
  • Predictive Value of Tests
  • Prospective Studies
  • Registries
  • Stents
  • Time Factors
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT03227588